Fixing Part D Coverage Gap ‘Cliff’ Is Right Way To Lower Costs, PhRMA Says
PhRMA pushing for legislation to address upcoming surge in Medicare Part D out-of-pocket spending requirements and reverse the recently-enacted increase in the discount on branded drugs in the coverage gap.
You may also be interested in...
Price inflation rebates are expected to generate $50bn in savings over 10 years, according to the Congressional Budget Office.
Performance of Johnson & Johnson’s blockbuster cardiovascular drug is one of the first prominent examples of how the 2019 increase in the discount from 50% to 70% is playing out in the market.
Office of Management and Budget health programs official highlights the Administration’s plan for updating and lowering costs in Medicare Part D, including point-of-sale rebates.